图书馆订阅: Guest
真核基因表达评论综述™

每年出版 6 

ISSN 打印: 1045-4403

ISSN 在线: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Strong Correlation between the Expression of CHEK1 and Clinicopathological Features of Patients with Multiple Myeloma

卷 30, 册 4, 2020, pp. 349-357
DOI: 10.1615/CritRevEukaryotGeneExpr.2020027084
Get accessGet access

摘要

Multiple myeloma (MM) is one of the most common malignancies, and the clinical outcome of patients with MM remains poor. Our objective is to screen biomarkers correlated with clinicopathological features and survival of patients with MM. A gene co-expression network was constructed to screen hub genes related to the three stages in the International Staging System (ISS) of MM. Functional analysis and protein-protein interaction analysis of the hub genes was performed. CHEK1, a gene most related to the ISS stages of MM, was selected for further clinical validation. A total of 780 hub genes correlated with ISS stages of MM were identified. Functional enrichment analysis of hub genes suggested that these genes were mostly enriched in several gene ontology (GO) terms and pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) that were involved in cell proliferation and immune response. Expression of the gene for the protein checkpoint kinase I (CHEK1) was increased in MM cells from newly diagnosed patients (P = 0.0304) and relapsed patients (P = 0.0002) as compared to normal plasma cells. Meanwhile, CHEK1 was increased more in MM patients with stage II disease (P = 0.0321) and stage III disease (P = 0.0076) than in those with stage I disease. Survival analysis indicated that MM patients in the group characterized by low CHEK1 expression were associated with better clinical outcomes in terms of time to progression, event-free survival, and overall survival. High expression of CHEK1 predicted poor clinical characteristics of MM patient, and our results indicate that it can be considered a biomarker for the diagnosis of MM.

参考文献
  1. J, Knauf W, Goldschmidt H. Diagnosis and treatment of multiple myeloma in Germany: Analysis of a nationwide multi-institutional survey. Ann Hematol. 2017;96(6):987-93.

  2. Gozzetti A, Papini G, Defina M, Bocchia M. Extramedullar myeloma relapses. Ann Hematol. 2012;91(9):1511-2?.

  3. Chan HSH, Chen CI, Reece DE. Current review on high-risk multiple myeloma. Curr Hematol Malig Rep. 2017;12(2):96-108.

  4. MacLennan IC, Drayson M, Dunn J. Multiple myeloma. BMJ. 1994;308(6935):1033-6.

  5. Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Myeloma in the real world: What is really happening? Clin Lymphoma Myeloma Leuk. 2017;17(3):133-44.e1.

  6. Liu X, Chen J, He YA, Meng X, Li K, He CK, Liu S. Comparing efficacy and survivals of initial treatments for elderly patients for elderly patients with newly diagnosed multiple myeloma: A network meta-analysis of randomized controlled rials. Onco Targets Ther. 2017;10:121-8.

  7. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Ann Hematol. 2017;96(3):449-59.

  8. Terpos E; International Myeloma Society. Multiple myeloma: Clinical updates from the American Society of Hematology Annual Meeting 2016. Clin Lymphoma Myeloma Leuk. 2017;17(6):329-39.

  9. Cejalvo MJ, de la Rubia J. Which therapies will move to the front line for multiple myeloma? Expert Rev Hematol. 2017;10(5):383-92.

  10. Cejalvo MJ, de la Rubia J. Clinical treatment of newly diagnosed multiple myeloma. Expert Rev Hematol. 2015;8(5):595-611.

  11. Rajkumar SV, Buadi F. Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol. 2007;20(4):665-80.

  12. Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol. 2009;46(2):110-7.

  13. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17.

  14. Yip AM, Horvath S. Gene network interconnectedness and the generalized topological overlap measure. BMC Bioinformatics. 2007;8:22.

  15. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543-53.

  16. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67(7):2982-9.

  17. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vul-nerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010;115(8):1594-604.

  18. Gaji RY, Behnke MS, Lehmann MM, White MW, Carruthers VB. Cell cycle-dependent, intercellular transmission of Toxoplasma gondii is accompanied by marked changes in parasite gene expression. Mol Microbiol. 2011;79(1):192-204.

  19. Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J, Stefanikova Z, Pour L, Hajek R. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med. 2016;14(1):150.

  20. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioin-formatics. 2004;20(3):307-15.

  21. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26(19):2363-7.

  22. Langfelder P, Horvath S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

  23. Oldham MC, Langfelder P, Horvath S. Network methods for describing sample relationships in genomic datasets: Application to Huntington's disease. BMC Syst Biol. 2012;6:63. doi: 10.1186/1752-0509-6-63.

  24. Li A, Horvath S. Network module detection: Affinity search technique with the multinode topological overlap measure. BMC Res Notes. 2009;2:142.

  25. Dong J, Horvath S. Understanding network concepts in modules. BMC Syst Biol. 2007;1:24.

  26. Liu XP, Yin XH, Meng XY, Yan XH, Wang F, He L. Development and validation of a 9-gene prognostic signature in patients with multiple myeloma. Front Oncol. 2019 Jan 8;8:615.

  27. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.

  28. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447-52.

  29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504.

  30. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2011;17(2):88-96.

  31. McNeely S, Beckmann R, Bence Lin AK. CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther. 2014;142(1):1-10.

  32. Sarmento LM, Barata JT. CHK1 and replicative stress in T-cell leukemia: Can an irreverent tumor suppressor end up playing the oncogene? Adv Biol Regul. 2016; 60:115-21.

  33. Zhou X, Liu W, Hu X, Dorrance A, Garzon R, Houghton PJ, Shen C. Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep. 2017;7(1):1535.

  34. Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017;7(3):473-83.

  35. Song N, Che X, Xu L, Qu J, Zheng H, Hou K, Qu X, Liu Y. A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells. Mol Cell Biochem. 2017;436Q-2):29-38.

  36. Lee HJ, Cao Y, Pham V, Blackwood E, Wilson C, Evangelista M, Klijn C, Stokoe D, Settleman J. Ras-MEK signaling mediates a critical Chk1-dependent DNA damage response in cancer cells. Mol Cancer Ther. 2017;16(4):694-704.

  37. Bargiela-Iparraguirre J, Prado-Marchal L, Fernan-dez-Fuente M, Gutierrez-Gonzalez A, Moreno-Rubio J, Munoz-Fernandez M, Sereno M, Sanchez-Prieto R, Perona R, Sanchez-Perez I. CHK1 expression in gastric cancer is modulated by p53 and RB1/E2F1: Implications in chemo/radiotherapy response. Sci Rep. 2016;6:21519.

  38. Bataille R, Annweiler C, Beauchet O. Multiple myeloma international staging system: "staging" or simply "aging" system? Clin Lymphoma Myeloma Leuk. 2013;13(6):635-7.

对本文的引用
  1. Huang Junting, Zhan Yating, Jiang Lili, Gao Yuxiang, Zhao Binyu, Zhang Yuxiao, Zhang Wenjie, Zheng Jianjian, Yu Jinglu, Identification of the Potential Prognosis Biomarkers in Hepatocellular Carcinoma: An Analysis Based on WGCNA and PPI, International Journal of General Medicine, Volume 14, 2021. Crossref

  2. Maojing Wang, Wenwen Li, Ding Li, Zhiwu Han, Analysis of the mechanism underlying the effects of cyclophosphamide against triple-negative breast cancer by an integrative bioinformatics approach, International Journal of Pharmaceutical Sciences and Developmental Research, 2021. Crossref

1453 文章浏览量 29 文章下载 统计数据
1453 文章浏览量 29 下载次数 2 Crossref 引用次数 Google
Scholar
引用次数

相似内容的文章:

Comprehensive Analysis of Epigenetic Associated Genes on Differential Gene Expression and Prognosis in Hepatocellular Carcinoma Journal of Environmental Pathology, Toxicology and Oncology, Vol.41, 2022, issue 1
Cong Li, Jianmin Mei, Jing Ding
Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Critical Reviews™ in Immunology, Vol.44, 2024, issue 4
Rongjin Zhou, Junguo Wang
Relationship between Topoisomerase II Alpha Overexpression and Prognosis in Chinese Gastric Cancer Patients Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 3
Binghe Xu, Fangchao Zheng, Feng Du, Jinhua Ma, Fei Ma, Ziyi Wang, Junhui Zhao, Shuyan Wang, Wei Ma, Li Dong, Guoshuang Shen, Yang Luo, Cunfang Shen, Jiuda Zhao, Xinfu Ma
Identification of Biomarkers Associated with Hepatocellular Carcinoma Stem Cell Characteristics Based on Co-Expression Network Analysis of Transcriptome Data and Stemness Index Critical Reviews™ in Eukaryotic Gene Expression, Vol.32, 2022, issue 2
Yubing Zhu, Jianjun Zou, Shaofang Feng, Yunxin Liu, Huiwen Mu, Zheng Zhao
Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma Journal of Environmental Pathology, Toxicology and Oncology, Vol.42, 2023, issue 4
Zhi Fu, Xiaoni Liu, Daming Gao, Tiezheng Wang, Dongdong Lin, Guang Yang

将发表的论文

PRMT6 promotes the immune evasion of gastric cancer via upregulating ANXA1 Liang Xu, Fenger Zhang, Binqi Yu, Shengnan Jia, Sunfu Fan PURPL promotes M2 macrophage polarization in lung cancer via regulating RBM4/xCT signaling Jipeng Guo, Chongwen Gong, Hao Wang SIAH1 promotes the pyroptosis of cardiomyocytes in diabetic cardiomyopathy via regulating IκB-α/NF-κB signaling Jinbin Wu, Yaoming Yan SLC7A2-mediated lysine catabolism inhibits immunosuppression in triple negative breast cancer Yuanyuan Sun, Yaqing Li, Chengying Jiang, Chenying Liu, Yuanming Song SIAH2-mediated degradation of ACSL4 inhibits the anti-tumor activity of CD8+ T cells in hepatocellular carcinoma Fangzheng Shu, Yuhua Shi, Xiangxiang Shan, Wenzhang Zha, Rengen Fan, Wanjiang Xue RBM15-mediated N6-methyl adenosine (m6A) modification of EZH2 drives the epithelial-mesenchymal transition of cervical cancer Ruixue Wang, Wenhua Tan Evidence-Based Storytelling and A Strategic Roadmap to Promote Cancer Prevention Via Adolescent HPV Vaccination in Northern New England Matthew Dugan, Gary Stein, Jan Carney, Sheila Clifford-Bova KDM4A-AS1 promotes cell proliferation, migration and invasion via the miR-4306/STX6 axis in hepatocellular carcinoma Wei Cao, Yuhan Ren, Ying Liu, Guoshu Cao, Zhen Chen, Fan Wang HDAC1-mediated downregulation of NEU1 exacerbates the aggressiveness of cervical cancer Nanzi Xie, Sisi Mei, Changlan Dai, Wei Chen Effect of miR-26b-5p on progression of acute myeloid leukemia by regulating USP48-mediated Wnt/β-catenin pathway Yu Xie, Lin Tan, Kun Wu, Deyun Li, Chengping Li
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain